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pneumoniae strains in hospital wastewater
Madam,
Carbapenem-hydrolysing b-lactamase KPC-producing isolates
of Klebsiella pneumoniae are a major problem and concern. The ﬁrst
KPC-producing isolate was K. pneumoniae from the USA, identiﬁed
in 1996, with subsequent identiﬁcations in China, Europe, Israel,
Central and Brazil.1 The KPC b-lactamases, a mostly plasmid-
encoded enzyme from K. pneumoniae, hydrolyse penicillins, cepha-
losporins, monobactams (aztreonam) and carbapenems, and are
weakly inhibited by clavulanic acid and tazobactam.2 Genetic anal-
ysis of blaKPC genes indicates that their mobility and dissemination
are related to a Tn3-based transposon, Tn4401, which is carried by
large plasmids varying in size and structure.3,4 During the last few
years, several carbapenem-hydrolysing b-lactamase KPC-
producing strains have been reported in Brazil in hospitalised
patients.5 This report describes the ﬁrst detection of KPC-2-
producing K. pneumoniae strains isolated inwastewater of a hospital
sewage treatment plant, Rio de Janeiro, Brazil.
In August and December 2008, two KPC-2-producing isolates
were recovered from efﬂuents of a sewage treatment plant that
services a hospital located in the metropolitan area of Rio de
Janeiro, Brazil. The strains were collected from clariﬁer tank
efﬂuent (N¼ 1) and chlorine contact tank efﬂuent (N¼ 1). The
antimicrobial susceptibility proﬁle was determined by the agar
diffusion method according to CLSI guidelines.6 After species iden-
tiﬁcation and antimicrobial susceptibility testing, isolates were
screened for the ESBL and carbapenemase-producing phenotypes
by the standard double-disc synergy test and a modiﬁed Hodge
test. The minimum inhibitory concentrations were determined
using Etest strips according to the manufacturer’s recommenda-
tions. Polymerase chain reaction testing was performed, as previ-
ously described, for the presence of the of blaKPC, blaTEM, blaSHV
and blaCTx-M genes. Ampliﬁcation products were puriﬁed and
sequenced in 3730 DNA Analyser (Applied Biosystems, CA, USA),
at the PDTIS-IOC DNA Sequencing Platform. Sequences were
compared with those in the GenBank database.
All K. pneumoniae isolates showed resistance to broad-spectrum
cephalosporins and carbapenems. We detected the co-resistance
of piperacillin/tazobactam, ciproﬂoxacin and trimethoprim-sulfa-
methoxazole. The K. pneumoniae strains were of two genotypes
(A, B). KPC-2-producing isolates harboured other b-lactam resis-
tance enzymes detected by the presence of the genes blaKPC, blaTEM,
blaSHV in all strains, whereas blaCTx-M was carried only by the geno-
type A. Sequencing of blaKPC revealed KPC-2 in all strains studied
(Table I).
The occurrence of KPC-2-producing K. pneumoniae isolates in
hospital is concerning and may have a real impact on public
health, principally by dissemination of these micro-organismsTable I
KPC-producing K. pneumoniae strains isolated from hospital wastewater
Strain Date Genotypes MIC (mg/L) b-Lactamases Co-resistancea
IPM MEM ETP
Kp 160 August
2008
A 2 4 >32 KPC-2; CTX-M;
SHV; TEM
SXT, TZP, CIP
Kp 232 December
2008
B 3 6 >32 KPC-2; SHV;
TEM
TZP
MIC, minimum inhibitory concentration; IPM, imipenem; MEM, meropenem; ETP,
ertapenem; SXT, trimethoprim-sulphamethoxazole; TZP, piperacillin/tazobactam;
CIP, ciproﬂoxacin.
a Intermediate was considered resistant in this analysis.and their plasmids into the environment. The rapid dissemina-
tion of KPC enzymes worldwide and the consequences for treat-
ment and infection control measures warrant a high degree of
awareness and monitoring of these enzymes. The low efﬁcacy
or lack of hospital sewage treatment may contribute to the
dissemination of KPC-2-producing and other multidrug-resistant
bacteria from the hospital to the environment. Thus, the hospital
efﬂuent may be considered as a potential vector of contamina-
tion and spread of these emerging resistance determinants and
multidrug-resistant micro-organisms. Approaches to reducing
environmental microbial contamination should be considered
by hospitals. However, the vast majority of hospitals in devel-
oping countries do not have sewage treatment plants, which
exacerbates the problem and may have important public health
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